For Patients

Disclaimer

ESMO Guides for Patients are prepared as a service to patients, to help patients, their relatives and caregivers better understand the nature of their cancer type and understand the best treatment choices available. Please note that information in these Guides for Patients does not replace a medical consultation. ESMO recommends that patients ask their doctors about what tests or types of treatments are needed for their type and stage of disease.

Patient information based on the ESMO Clinical Practice Guidelines - Declaration of interest

Aglione Antonio: No conflicts of interest to declare
Aguarón Alfonso: No disclosure at time of going online
Allum William: No conflicts of interest to declare
Apostolidis Kathi: A volunteer cancer patient advocate and the Vice-President of ECPC, the European Cancer Patient Coalition. ECPC has received support to carry its action plan from AbbVie, Amgen, AstraZeneca, Baxter, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly & Co, Gilead, Helsinn, Ipsen, Johnson & Johnson, Merck, MSD, Novartis, Pfizer, and Roche.
Arnold Dirk: Research grants – Roche, Sanofi
Baccarani Michele: Honoraria from Novartis, Bristol-Myers Squibb, Pfizer and Ariad for participation to advisory boards and as a speaker at scientific and educational meetings.
Bayne Louise: No disclosure at time of going online
Beaumont Stéphane: No disclosure at time of going online
Beveridge Jane: No conflicts of interest to declare
Bjerrum Thisted Lise: No conflicts of interest to declare
Blay Jean-Yves: No conflicts of interest to declare
Boland Greet: No conflicts of interest to declare
Bolaños Natacha: No disclosure at time of going online
Bouche Gauthier: No conflicts of interest to declare
Bouguet Guy: No disclosure at time of going online
Bellmunt Joaquim: Consultant or Advisory Role - Lilly, Pierre Fabre and Sanofi Aventis
Billiau An: Medical writer of Celsus Medical Writing LLC. – Honoraria from Anticancer Fund
Bosman Patricia: No conflicts of interest to declare
Bramley Claire: Stock ownership: GSK
Brandt Juliane: Speaker’s honoraria: AbbVie, Nationale Gesundheitsakademie, Roche
Buske Christian: Research funds: Roche, Janssen; Speaker’s bureau: Roche, Janssen, Pfizer
Cardoso Fatima: Receipt of honoraria or consultation fees: Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, GlaxoSmithKline, Macrogenics, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, Roche, Sanofi, Seattle Genetics, Teva
Casali Paolo: Consultancy/Honoraria: Amgen Domplé, ARIAD, Bayer, GlaxoSmithKline, Infinity, Janssen Cilag, Merck Sharp & Dohme, Novartis, Pfizer, PharmaMar, Sanofi
Casanovas Taltavull Teresa: No disclosure at time of going online
Coleman E. Rob: Consulting and/or speaker fees: Amgen, Astellas, Eisai, Genomic Health, Inbiomotion and Scancell; a patent holder for a biomarker developed by Inbiomotion; a former employee of prIME Oncology
Colia Vittoria: No conflicts of interest to declare
Colombo Nicoletta: Consulting and advisory services, speaking or writing engagements, public presentations: Roche, AstraZeneca, Pharma Mar, Tesaro (GSK), Clovis, Advaxis, Pfizer, Takeda, Immunogen, Biocad; Institutional support for clinical trials or contracted research: Roche, Pharma Mar and AstraZeneca
Cunningham David: Research funding - Roche and Amgen
Curigliano Giuseppe: Honoraria for speaker’s engagement: Roche, Seattle Genetics, Novartis, Lilly, Pfizer, Foundation Medicine, Nanostring, Samsung, Celltrion, BMS, MSD; Honoraria for providing consultancy: Roche, Seattle Genetics, Nanostring; Honoraria for participating in Advisory Board: Roche, Lilly, Pfizer, Foundation Medicine, Samsung, Celltrion, Mylan; Honoraria for writing engagement: Novartis, BMS; Honoraria for participation in Ellipsis Scientific Affairs Group; Institutional research funding for conducting phase I and II clinical trials: Pfizer, Roche, Novartis, Sanofi, Celgene, Servier, Orion, AstraZeneca, Seattle Genetics, AbbVie, Tesaro, BMS, Merck Serono, Merck Sharp Dome, Janssen-Cilag, Philogen, Bayer, Medivation, Medimmune
Curtis Christopher: No disclosure at time of going online
De Lorenzo Francesco: A volunteer cancer patient advocate and the President of ECPC, the European Cancer Patient Coalition. ECPC has received support to carry its action plan from AbbVie, Amgen, AstraZeneca, Baxter, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly & Co, Gilead, Helsinn, Ipsen, Johnson & Johnson, Merck, MSD, Novartis, Pfizer, and Roche.
Deschamps André: Non-financial interest for leadership role: Member of Board of Directors of Europa Uomo
Diamanti Orejeta: No conflicts of interest to declare
Dodlek Nikolina: No conflicts of interest to declare
Douillard Jean-Yves: No conflicts of interest to declare
Dowling John: No disclosure at time of going online
Dreyling Martin: Advisory Board: Bayer, Celgene, Gilead, Janssen, Pfizer; Consultancy/Honorari: Celgene, Janssen, Mundipharma, Pfizer, Roche; Research funding to the institution: Celgene, Janssen, Pfizer, Mundipharma, Roche.
Dummer Reinhard: Research funding - Astra Zeneca, Novartis, Cephalon, Merck Sharp & Dhome, Transgene, Bristol-Myers Squibb, Roche, GlaxoSmith Klein, Bayer; Consultant or Advisory Board: Astra Zeneca,Novartis, Cephalon, Merck Sharp & Dhome, Transgene, Genta, Bayer, Roche, Bristol-Myers Squibb, GlaxoSmith Klein, Spirig.
Fenlon Deborah: No disclosure at time of going online
Fey Martin: No conflicts of interest to declare
Filicevas Alex: No disclosure at time of going online
Florindi Francesco: No conflicts of interest to declare
Fowler Matthew: No conflicts of interest to declare
Freitas Jorge: No conflicts of interest to declare
Geissler Jan: No disclosure at time of going online
Giles Rachel H.: Speakers’ Honoraria from Ipsen and Novartis. The IKCC receives project and educational funds from BMS, Ipsen, Exelixis, MSD, Pfizer, Novartis, Eisai, and Roche
Glimelius Bengt: No conflicts of interest to declare
Gonzato Ornella: No conflicts of interest to declare
Haanen John: Honoraria from Amgen, Merck, MSD, Helsinn, Tesaro and Hexaland; A member of the advisory board of Merck, MSD, Helsinn and Tesaro
Hewitt Julie: No conflicts of interest to declare
Horwich Alan: His institution is inventor of abiraterone and receives royalty payments; no personal conflicts.
Hotlet Rüsz Maria: No conflicts of interest to declare
Jerome Olivier: No disclosure at time of going online
Jewel Anna: No conflicts of interest to declare
Jezdic Svetlana: No conflicts of interest to declare
Jordan Karin: Personal financial interests, honoraria for speaker, consultancy or advisory role, royalties, direct research funding: MSD, Merck, Amgen, Hexal, Riemser, Helsinn, Tesaro, Kreussler, Voluntis, Pfizer, Pomme-med, Pharma Mar, Shire, ClinSolResearch, G1 Therapeutics, Annals of Oncology, UpToDate, Prime Oncology, medupdate, arttempi; Institutional financial interests: MSD, Helsinn, Riemser, Acacia, Menarini
Jost Lorenz: No conflicts of interest to declare
Ihlen Regine Deniel: Lung Cancer Europe (LuCE) is a non-profit organisation whose activities are funded by balanced support from BMS and MSD
Keilholz Ulrich: Honoraria: Amgen, BMS, GSK, Glycotope, MerckSerono, Merck/MSD, Pfizer; Research support: Pfizer, MerckSerono, Innate, Sirtec.
Khort Holbrook: No conflicts of interest to declare
Kinneally Ada: No conflicts of interest to declare
Kirby David: No conflicts of interest to declare
Koller Antje: No conflicts of interest to declare
Korenjak Marko: No disclosure at time of going online
Kornek Gabriella: No disclosure at time of going online
Kosmidis Paris: No conflicts of interest to declare
Labianca Roberto: Research grants – Roche, Sanofi
Lacointe-Artzner Estelle: No disclosure at time of going online
Ladetto Marco: No conflicts of interest to declare
Lang Tamika: Former employee of the Myeloma Patients Europe; Currently external consultant in Myeloma Patients Europe for medical/clinical/educational affairs; Ownership (medical/educational consultancy): Patient-Centered Medical and Educational Consultants, LLC.; Invited speaker fees through consultancy: Patvocates/ European Idiopathic Pulmonary Fibrosis Federation; Non-financial interests: Work on IMI Prefer, CARAMBA, IMI Harmony consortiums/ EU funded projects during employment in the Myeloma Patients Europe; Other: A licensed physician assistant in the United States, but not practicing clinically
Lawless Roisin: No conflicts of interest to declare
Lebrocquy Isabelle: No conflicts of interest to declare
Lewington Michelle: No conflicts of interest to declare
Licitra Lisa: Advisory Board: Bristol-Myers Squibb, GlaxoSmith Klein, Ely Lilly, Merck-Serono and Amgen; Institutional funds for clinical studies and research activities in which she is involved from EISAI, Exelixis, ly Lilly, Merck-Serono, Amgen; Travel coverages to attend medical meetings Merck-Serono.
Lindsell Sarah: No conflicts of interest to declare
Lordick Florian: Honoraria: Amgen, AstraZeneca, Astellas, Biontech, BMS, Eli Lilly, Elsevier, Excerpta Medica, Imedex, Infomedica, Iomedico, Medscape, MedUpdate, Merck Serono, MSD, Oncovis, Promedicis, Roche, Springer Nature, StreamedUp! and Zymeworks.
MacKay Pam: No disclosure at time of going online
Makaroff Lydia: Employee of the European Cancer Patient Coalition. The European Cancer Patient Coalition receives financial support from AbbVie, AstraZeneca, Baxter, BMS, Boehringer-Ingelheim, Celgene, Elly Lilly & Co, Genomic Health, Helsinn, Ipsen, Johnson & Johnson, LEO Pharma, Merck, MSD, Novartis, Pfizer, Roche, Takeda and Tesaro
Marchesi Vanessa: No conflicts of interest to declare
Margulies Anita: No conflicts of interest to declare
Martinelli Erika: Honoraria for lectures and advisory boards: Roche, Amgen, Servier and Sanofi
Mastris Ken: No conflicts of interest to declare
Metro Giulio: Honoraria from Anticancer Fund
Michiels Annemie: No conflicts of interest to declare
Mitsimponas Nikolaos: No conflicts of interest to declare
Moreau Philippe: Advisory Boards and Honoraria: Celgene, Janssen, Takeda, Amgen and Novartis.
Morement Helen: No disclosure at time of going online
Mussetti Alberto: No conflicts of interest to declare
Novello Silvia: Speaker’s bureau: Eli Lilly, Bristol-Myers Squibb, Merck Sharpe & Dohme, AstraZeneca, Boehringer Ingelheim, Roche, Incyte, Takeda
Okines Alicia: Honorarium and travel support – Roche
Oliver Kathy: Honoraria for Healthcare Advisory Board (“HAB” – patient advocacy board) – GlaxoSmithKline; Honoraria for Global Council of the Patient Access to Cancer Care Excellence (PACE) initiative – Eli Lilly; Honoraria as a member of E-PALCO (European Cancer Patient Leaders Council) – Novartis; Honoraria for Worldwide Oncology Advocacy Advisory Board – Bristol-Myers Squibb; Honoraria for Advisory meeting – AbbVie; Honoraria for consultancy – Eli Lilly; Speaker fee: Bayer; Consultancy work EORTC/SPAEN Training Course in “Understanding Clinical Research”; Honoraria for consultancy work SPAEN training course in patient advocacy. KO is a Chair and Co-Director of the International Brain Tumour Alliance (IBTA) that accepted financial support and support in kind either directly or as part of a wider grouping of patient organisations from the following companies and trusts: Accuray, Antisense Pharma, Apogenix, Archimedes, Ark Therapeutics, Astra Zeneca, Boehringer Ingelheim, Brain Tumor Network (USA), Brain Tumor Resource and Information Network (USA), Bristol-Myers Squibb (BMS), Celldex Therapeutics, Crusade, Dijon Designs (UK), Elekta, Eli Lilly, Gerry & Nancy Pencer Brain Trust (Canada), Gosling Foundation (UK), GlaxoSmithKline (GSK), Ivy Foundation (USA), Lilly, Link Pharmaceuticals, Magforce, Medac, Merck Serono, Merck, MGI Pharma, MSD Oncology, NeoPharm, Neuroendoscopy (Australia), Northwest Biotherapeutics, Novartis, Novocure, Pediatric Brain Tumor Foundation (USA), Pfizer, Photonamic, Roche, Schering-Plough (Global), Sontag Foundation (USA), Spink (UK), to-BBB, Vane Percy (UK), VBL Therapeutics, Wallerstein Foundation (USA).
Pelouchova Jana: No disclosure at time of going online
Pentheroudakis George: Consulting and advisory services, speaking or writing engagements, public presentations: Amgen, Merck, AstraZeneca, Roche, BMS, MSD, Lilly; Direct research support: Boehringer, Merck, Amgen, AstraZeneca, Roche, Enorasis, BMS, Lilly; Institutional financial support for clinical trials or contracted research: Boehringer, Merck, Amgen, AstraZeneca, Roche, Lilly, Abbvie, Debiopharm, Ipsen
Peters Solange: Consultation / Advisory role (all fees to institution): Abbvie, Amgen, AstraZeneca, Bayer, Biocartis, Bioinvent, Blueprint Medicines, Boehringer-Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F. Hoffmann-La Roche, Foundation Medicine, Illumina, Janssen, Merck Sharp and Dohme, Merck Serono, Merrimack, Novartis, Pharma Mar, Pfizer, Regeneron, Sanofi, Seattle Genetics,Takeda and Vaccibody; Talk in a company’s organised public event (all fees to institution): AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, Illumina, Merck Sharp and Dohme, Novartis, Pfizer, Sanofi, Takeda; Receipt of grants/research supports (all fees to institution): (Sub)investigator in trials (institutional financial support for clinical trials) sponsored by Amgen, AstraZeneca, Biodesix, Boehringer-Ingelheim, Bristol-Myers Squibb, Clovis, F. Hoffmann-La Roche, Illumina, Merck Sharp and Dohme, Merck Serono, Novartis, and Pfizer
Planchard David: Honoraria: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Merck, Merck Sharp and Dohme Oncology, Novartis, Pfizer, prIME Oncology, Roche; Consulting, advisory role or lectures: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Merck Sharp and Dohme Oncology, Novartis, Pfizer, prIME Oncology, Roche; Travel grants: AstraZeneca, Roche, Novartis, prIME Oncology and Pfizer
Plataniotis George: No conflicts of interest to declare
Plate Ananda: No disclosure at time of going online
Polińska Agata: Honoraria: Bayer; Institutional financial interest - oncology health policy grant: MSD; Grants to Foundation for educational projects: Roche, Bayer, Gilead Science, Celgene, Janssen-Cilag, Novartis, Sanofi-Aventis, MagForce, Danone, Takeda, Pierre Fabre, Bristol Myers Squibb, Nutricia, AbbVie, Astellas Pharma, Servier Polska, MSD Polska, AstraZeneca, Boehringer-Ingelheim, Amgen
Powles Thomas: Honoraria for participation in Advisory Board: Astellas, AstraZeneca, Bristol Myers-Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, Seatlle Genetics; Fees for covering travel/accommodation expenses: AstraZeneca, Ipsen, MSD, Pfizer, Roche; Sponsorship for podcast: Mashup Ltd; Research grant to institution: Astellas, AstraZeneca, Bristol Myers-Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, Seattle Genetics
Provenzano Salvatore: No conflicts of interest to declare
Rapetti Simonetta: No disclosure at time of going online
Rauh Stefan: No conflicts of interest to declare
Rek Anna: Employee of the European Cancer Patient Coalition. The European Cancer Patient Coalition receives financial support from AbbVie, AstraZeneca, Baxter, BMS, Boehringer-Ingelheim, Celgene, Elly Lilly & Co, Genomic Health, Helsinn, Ipsen, Johnson & Johnson, LEO Pharma, Merck, MSD, Novartis, Pfizer, Roche, Takeda and Tesaro
Senkus Elzbieta: Receipt of grants/research support: Amgen, Astellas, AstraZeneca, Bayer, BMS, Janssen, Pfizer, Pierre Fabre, Roche; Other support (travel expenses): Amgen, Astellas, AstraZeneca, Bayer, BMS, Janssen, Pfizer, Novartis, Roche
Sessa Cristiana: No conflicts of interest to declare
Soo Ross: Honoraria: AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Ignyta, Lilly, Merck, Novartis, Pfizer, Roche, Taiho, Takeda, Yuhan; Direct research funding: AstraZeneca, Boehringer Ingelheim; Institutional financial interests: Abbvie, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Ignyta, Merck, Merck Serono, Novartis, Pfizer, Roche, Takeda, Yuhan
Spanic Tanja: Personal financial interest: Roche, AstraZeneca, Pfizer, Bayer
Spurrier Gilliosa: MelanomeFrance has received project funding from Roche, Novartis, BMS, Amgen - Support never includes editorial rights or influence on MelanomeFrance’s programme or activities; GS has received Patient Advocate Honoraria for Advisory boards from Amgen, BMS and Novartis
Stacchiotti Silvia: Research grants: Novartis, Pfizer, PharmaMar, GlaxoSmithKline, Amgen, Bayer
Stahl Michael: No conflicts of interest to declare
Stunt Ali: No disclosure at time of going online
Stupp Roger: Honoraria or consulting fee (paid to institution): Roche, Merck KGaA/EMD-Serono, MSD/Merck & Co, Pfizer, Ipsen Pharma, Novartis.
Sverre Hans: No disclosure at time of going online
Tanay Mary: No conflicts of interest to declare
Tassini Umberto: No conflicts of interest to declare
Trigoso Arjona Eugenia: Non-financial interest: Member of EBMT, Member of EBMT Nurses Group, Member of EONS Education Working Group
Ugarte Ana: No conflicts of interest to declare
Valle Juan: Honoraria/consultancy: Lilly, AstraZeneca and Sirtex; Rresearch support: Lilly, AstraZeneca and NuCana
Vallejo Ana: No disclosure at time of going online
Vallone Stefania: No conflicts of interest to declare
Van Cutsem Eric: Research funding – Amgen, MerckSerono, Phizer, Roche, Sanofi-Aventis
van Muilekom Erik: No disclosure at time of going online
Villa Giulia: No conflicts of interest to declare
Voitiekute Tanya: No disclosure at time of going online
Voiculescu Vlad: No conflicts of interest to declare
Vyas Malvika: No conflicts of interest to declare
Waldmann Anita: No conflicts of interest to declare
Wartenberg Markus: No disclosure at time of going online
Wilson Roger: No disclosure at time of going online
Zwinkels Hanneke: No conflicts of interest to declare